Articles tagged with Psychopharmacology
Researchers propose using carefully designed combinations of approved drugs to create a more convincing placebo, limiting participant disclosure, and rigorous testing to ensure effective masking. This approach, called UMBRAA, aims to overcome the challenge of distinguishing between psychedelic effects and the power of expectation.
A new study reveals that psychedelics and anesthetics create 'mirror image' patterns in brain organization, with opposite network features. Researchers found that psychedelics increase functional connectivity, while sleep and anesthesia reduce it.
Researchers found that LSD, psilocybin, and 2C-B affect brain activity in distinct ways, with different changes observed during and after acute effects. The study provides a biological starting point for investigating individualized treatments for mental health disorders.
A new study by UTEP researchers found that early nicotine vapor exposure increases nicotine seeking behavior in adult male rats, even after long periods of abstinence. The study suggests that early exposure to nicotine vapor can lead to durable changes in the brain's reward system, driving nicotine-seeking behavior into adulthood.
A Charité study analyzed therapist experiences worldwide to create a profile for successful psychedelic-assisted therapy. Key characteristics include stable environment, support from loved ones, and specific personality traits that contribute to treatment success.
A new study found that nearly 1,200 TBI respondents used psychedelics to treat or manage physical health conditions, with 208 participants using them to manage brain injury-related symptoms. Researchers reported a 90% self-reported symptom improvement rate.
Dr. Gobbi challenges the global drug-development system, stating that promising treatments for mental illness are failing to reach patients due to venture capital and profit motives. Her research focuses on cannabis, melatonin, and psychedelics, with a goal of improving public-health decisions and treatment outcomes.
Treatment with psychedelics triggers large-scale reconfiguration of brain network dynamics driven by myelin remodeling, which might augment or sustain therapeutic effects. The study suggests that enhancing myelination could be a viable strategy to promote longer-term neural health and recovery from PTSD.
The study found that opioids provide only small, time-limited pain relief for certain pain conditions, such as stomach pain and dental surgery. Regular use of opioids comes with a risk of harm, including dependence and overdose.
Chronic alcohol consumption alters endocannabinoid gene expression in reward- and decision-related brain regions, offering insights into addiction biology. This study reveals changes in CB1 and CB2 receptor genes, as well as GPR55 and FAAH enzymes, potentially leading to targeted therapeutic strategies.
A study found that nearly a quarter of young people taking psychotropic medications were prescribed multiple medications with serious interaction risks. The greatest increases in medication use were seen among children and young adults, highlighting the need for careful monitoring and research on long-term safety.
A recent landmark study identifies adenosine as the critical mediator of rapid antidepressant action, connecting ketamine, ECT, and hypoxia. The discovery raises questions about the potential interference of caffeine with these treatments, highlighting the need for further research on adenosinergic modulation in depression.
A systematic review synthesizes clinical and preclinical evidence on psilocybin's effects on obsessive-compulsive behaviours, revealing consistent anti-compulsive effects in human patients and validated animal models. Single doses of psilocybin led to rapid symptom reductions in clinical populations.
Psychedelic substances profoundly alter our perception of time, inducing temporal distortions that offer unprecedented insights into consciousness. By suppressing the default mode network and modulating multiple brain regions, psychedelics provide unique windows into brain function and mental health treatment.
The review synthesizes clinical evidence on MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), autism spectrum disorder, eating disorders, and existential distress. It identifies consistent patterns across diverse clinical applications and highlights the therapeutic potential of MDMA, including its oxytocin-mediated ...
A renowned geneticist, Dr. Martin Alda, has made a groundbreaking discovery that bipolar disorder is composed of multiple genetically distinct disorders, transforming treatment approaches worldwide. His research also highlights the importance of combining basic research with clinical observations to advance psychiatric care.
Research suggests that psilocybin may not be an effective treatment for postpartum depression due to its potential to amplify anxiety and depressive-like symptoms in mouse mothers. The study found that offspring raised by psilocybin-treated mothers exhibited anxiety and depression-like symptoms long into adulthood.
Dr. Harriet de Wit's groundbreaking research bridges animal and human drug studies, demonstrating that MDMA enhances feelings of social connectedness and challenging addiction treatment strategies. Her discoveries have profound implications for treating trauma-related disorders globally.
Researchers Dr. Sharday Mosurinjohn and Dr. Richard Ascough critique the 'psychedelic mysteries hypothesis' in a new article, arguing that it relies on circumstantial evidence rather than solid historical scholarship. They advocate for responsible curiosity and a focus on living traditions to unlock psychedelic wisdom.
New research highlights TNF-α system's involvement in central nervous system disorders such as depression, narcolepsy, multiple sclerosis, Alzheimer's, and Parkinson's disease. The study reveals that psychotropic drugs may activate the TNF-α system through various mechanisms.
Dr. Danielle Beckman's research uses animal models to understand how viruses like COVID-19 trigger neurological damage and accelerate Alzheimer's disease. Her work has established critical connections between viral infections and neurodegenerative processes.
Researchers at UC Davis have developed a new method called CaST to track the activation of brain neurons and biomolecules by psychedelic drugs. The tool allows scientists to study the cellular mechanisms behind psychedelic treatments for brain disorders, such as depression and post-traumatic stress disorder.
Scripps Research scientists have identified the posterior paraventricular nucleus of the thalamus as a key brain region involved in stress-induced oxycodone relapse. Exposure to suvorexant, which blocks orexin signaling, reduced drug-seeking behavior and prevented relapse.
The latest issues of APA journals focus on treatment options for youth with irritability, exploring collaborative psychopharmacology approaches. Additionally, the studies examine disparities in the use of restraint among psychiatric patients.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Researchers are exploring psychedelic-based treatments as a potential game-changer for patients with post-traumatic stress disorder (PTSD) and substance use disorders. Studies have shown improvements in symptoms of both conditions, offering new hope for those who have struggled with treatment-resistant disorders.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
The new guidelines, developed by 22 experts across three continents, provide a comprehensive approach to diagnosing and treating catatonia. The recommendations include the use of benzodiazepines and electroconvulsive therapy, with attention to special requirements for certain groups.
A recent renaissance in psychedelic research investigates the cognitive effects of these drugs, shifting from mathematical modeling to behavioral and clinical studies. Studies have found that psychedelics can increase spontaneous creative insights while decreasing task-specific creativity, as well as affect memories in a malleable way.
The American Psychiatric Association's December journal issues explore new therapeutic approaches involving psychopharmacology, digital technology, and fMRI neurofeedback. The APA also highlights its vision to ensure access to quality psychiatric diagnosis and treatment.
Research at the University of Reading found that high-dose Vitamin B6 supplementation reduced feelings of anxiety and depression in young adults. The study links Vitamin B6 to its calming effect on the brain, which may help alleviate mood disorders.
A new study led by UCL and King's College London researchers found that adolescents are three times more likely to develop a cannabis addiction than adults. However, they do not appear to be at increased risk of subclinical depression or anxiety. In contrast, adult users who become addicted may experience worsening mental health symptoms.
A new study suggests that supplementing a diet with Ascidiacea, also known as sea squirts, reverses some main signs of aging in animal models. The researchers found that plasmalogens, vital to body processes, decrease with age and contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
A study found that caffeine increases alertness and detection accuracy for moving targets, improving reaction times and visual processing. Researchers tested participants' dynamic visual acuity skills before and after caffeine ingestion, showing significant improvements in accuracy and speed.
A new study analyzing medical evidence on domestic mass shooters in the US finds that a majority of perpetrators have psychiatric disorders without treatment, increasing risk of violence. The researchers identified signs and symptoms of brain illness in 32 out of 35 perpetrators, with most having schizophrenia or other diagnoses.
The practice of microdosing psychedelic drugs to enhance mood and productivity lacks robust scientific evidence. Despite reports of positive experiences, the team presents a lack of controlled studies, uncertain doses, and safety concerns, highlighting the need for rigorous research.
A comprehensive review of new stimulant formulations for treating ADHD provides clinicians with a valuable guide to choosing effective treatments. The review highlights novel delivery systems, advances in individual variability, and nuanced approaches to treatment.
A new study found that CBD buffers against THC's effects on the brain, potentially making higher-CBD cannabis strains less harmful. The research used fMRI to gauge how different cannabis strains impact brain function.
A simulated study found that exposure to SSRIs differed among poor, normal, rapid, and ultra-rapid metabolizers. This information could inform SSRI dosing to optimize efficacy and minimize adverse effects.
A new study found that delayed-release, extended-release methylphenidate can be taken in the evening without affecting its efficacy for at least 10 hours. This formulation may provide a more flexible treatment option for adults with attention deficit hyperactivity disorder (ADHD).
A new study published in the Journal of Child and Adolescent Psychopharmacology found that saffron was as effective as methylphenidate in controlling ADHD symptoms in children and teens. The researchers also noted similar side effects, making saffron a promising herbal alternative for treating ADHD.
Dasotraline shows significant improvement in efficacy in the treatment of ADHD compared to placebo, particularly at a dose of 4mg/day. The study also assesses safety and subgroup analysis, providing hope for new treatments with fewer side effects.
A survey of psychiatrists found that a substantial proportion believe their electronic prescribing systems provide incorrect warnings, potentially leading to inadequate treatment. The study highlights the need for more research on the accuracy and usefulness of automated alerts.
A new study found that ketamine significantly decreased symptoms in adolescents with treatment-resistant depression, with 38% meeting clinical response criteria. The treatment was well-tolerated and has sparked excitement about a potential new agent for this population.
Dr. Koplewicz highlights the urgent need to prioritize mental health in response to mass shootings like Parkland. He emphasizes that social isolation can exacerbate emotional problems and calls for better support systems in schools.
New research fails to support desvenlafaxine's effectiveness in treating major depressive disorder (MDD) in children and adolescents. A recent study found that neither a low nor high dose of the medication was significantly more effective than placebo.
A phase 3 study of children ages 6-12 years with ADHD found that a delayed-release, long-acting formulation of methylphenidate improved ADHD symptoms and functional impairment in the morning. The medication provided sustained release throughout the day, reducing the need for multiple doses.
A study found that extended-release guanfacine only showed a small reduction in tic severity among children with chronic tic disorders, with no significant difference between the drug and placebo. The medication was associated with common side effects such as fatigue, dry mouth, and headache.
A comprehensive treatment framework is presented to guide the management of children with PANS/PANDAS, focusing on psychiatric interventions, infection prevention, and immunomodulatory therapies. The guidelines aim to improve symptom relief, functioning, and adherence to therapeutic interventions.
Combining moderate alcohol consumption with moderate sleep restriction leads to increased deficits in attention and drowsiness compared to either factor alone. Performance impairment remains apparent even with frequent breaks, emphasizing the need for adequate rest before driving after consuming alcohol.
A pilot study of guanfacine, an alpha2-agonist, found the drug safe and well-tolerated in pediatric patients with anxiety disorder. The study suggests potential effectiveness and opens doors to further clinical testing.
A systematic review of 35 studies found that longer duration of untreated childhood schizophrenia-spectrum psychosis is associated with poorer functional improvement. Children and adolescents with EOS often experience frequent pre- and co-morbid conditions, leading to worse outcomes.
A meta-analysis of clinical trials found that aripiprazole significantly reduced total tics and tic severity in children with Tourette's disorder. The medication was safe, with common side effects including drowsiness and nausea.
Maladaptive and impulsive aggression is a disabling symptom in children with psychiatric disorders, characterized by explosive behavior triggered by routine cues. The development of effective treatments requires better descriptive and quantitative methods to characterize this disorder.
Researchers found that intoxication and distractions further impair driving abilities, even at low blood alcohol levels. The study suggests reducing the legal limit may not be enough to ensure safe driving.
A new study published in Journal of Child and Adolescent Psychopharmacology found that Evekeo improves ADHD symptoms and behavior in children with ADHD. The medication, given once or twice daily, shows significant improvement in ADHD rating scores, especially within the first 10 hours post-dose.
A new study found that anhedonia, the inability to gain pleasure, is associated with more severe depression and worse outcomes in adolescents. Anhedonia severity showed a significant correlation with overall outcomes, including illness severity and episode duration.
A consensus statement from leading clinicians and researchers recommends a systematic approach to evaluating youngsters with sudden onset of neuropsychiatric symptoms, including obsessive-compulsive disorder. The guidelines aim to clarify diagnostic boundaries, develop evaluation strategies, and identify urgently needed studies.
A nationwide study found a small but statistically significant cardiovascular risk associated with stimulant treatment in children with ADHD. The researchers also reported on the relationship between specific stimulant dose and risk of a cardiovascular event.
Recent studies found that duloxetine and fluoxetine showed no significant difference in response rates when treating major depressive disorder (MDD) in children and teens. The authors suggest that complexity of the studies may be a factor, but also offer valuable insights for designing future investigations.